Aktie A2PXV9 ENDONOVO THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Endonovo Therapeutics, Inc.

Aktien

A2PXV9

US29272H3003

ENDV

Markt geschlossen - OTC Markets
Andere Börsenplätze
 15:46:50 14.05.2024 		% 5 Tage % 1. Jan.
0,0015 USD -25,00 % Intraday Chart für Endonovo Therapeutics, Inc. -40,00 % -82,76 %
2023 Endonovo Therapeutics, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Sofpulse® von Endonovo Therapeutics, Inc. erhält die FDA-Zulassung in Taiwan CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Endonovo's SofPulse® Secures Taiwan FDA Approval
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
Endonovo Pending Agreement to Develop Telehealth Division
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Endonovo Launches SofPulse® into the Veterans Administration
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment
ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PXV9 Aktie
  4. Nachrichten Endonovo Therapeutics, Inc.
  5. Andere Sprachen